Abstract Objective: The use of corticosteroid in Kawasaki disease (KD) remains controversial among current guidelines. The objective of this study is to summarize the effectiveness and safety of corticosteroid to prevent coronary arterial lesions in Kawasaki disease, both as initial and rescue therapy. Methods: The Medline, EMBASE, Google scholar, Cochrane Central Register of Controlled Trials databases, ClinicalTrials.gov, and Japanese Institutional Repositories Online were searched for studies up to 31 March 2017. Studies that compared incidence of coronary artery lesions between regimens with corticosteroid and regimen without it in a well-defined controlled group were included. The incidence of coronary artery lesion was analyzed by meta-analysis. Results: Nineteen studies published between 1999 and 2016 fulfilled eligibility criteria. There were 3591 patients included for analysis. There was a significant reduction in incidence of coronary artery lesions with usage of corticosteroid with a pooled odds ratio of 0.72 (95% CI 0.57e0.92; p Z 0.01) than that without usage of corticosteroid. In general, a greater effect was seen in the patient received corticosteroid as initial and adjuvant therapy with intravenous immune globulin (pooled odds ratio 0.39, 95% CI 0.21e0.73, p Z 0.007) than those who received corticosteroid as rescue therapy. The risk reduction was statistically significant in Japanese groups (OR 0.56, 95% CI 0.42e0.75 in fixed effects model) but not significant in non-Japanese groups (OR 1.45, 95% CI 0.91e2.30 in fixed effects model).
Introduction
Kawasaki disease is an acute inflammatory disease, associated with vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries. Kawasaki disease is most common cause of acquired heart disease in the children in the developed world.
1e3 Coronary artery lesions (CAL) occur in 15e25% of untreated patients. 4 Because randomized controlled studies and meta-analysis 5, 6 have confirmed that Intravenous immune globulin (IVIG) plus aspirin compared with aspirin alone reduces the risk of CAL, IVIG has been taken as standard treatment. The role of corticosteroid, on the other hand, is controversial. Reluctance to employ corticosteroid regimens in acute Kawasaki disease derived from an early study, 7 but the selection bias in that study was obvious, that is, only sickest patients received corticosteroid. In the light of Japanese RAISE study, 8 Japanese Society of Pediatric suggested that corticosteroid may be used as initial therapy if patients' risk score indicates severe Kawasaki disease in their revised guideline. They also endorsed corticosteroid as rescue therapy for IVIG resistant patients. 9 The 2004 American Heart Association guideline withheld recommendation of primary corticosteroid as the American Pediatric Heart Network study had not been completed then. 4, 10 Therefore, given the controversy of corticosteroid therapy, we performed this study to measure the overall effectiveness of corticosteroid on preventing coronary artery abnormalities.
Methods
This meta-analysis was performed under the framework of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). 11 
Eligibility criteria
Studies were considered eligible if the available data contained sufficient information to allow assessment of validity and incidence. To be eligible the study must meet the following criteria 1) The study followed the established diagnostic criteria of Kawasaki disease for all patients.
2) The study included corticosteroid as treatment within one month from diagnosis. 3) There was an explicit treatment process. 4) The study had stated definition of coronary artery lesions and echocardiography or cardiac catheterization was adopted to detect them.
Information source
The MEDLINE (through PubMed), EMBASE, Google scholar, Cochrane Central Register of Controlled Trials databases, ClinicalTrials.gov, and Japanese Institutional Repositories Online were searched up to 31 March 2017.
Search and study selection
The topic search terms were used in combination with the Cochrane highly sensitive search strategy for identifying randomized controlled trials. We used the following free text and MeSH terms to search all trials registers and databases: mucocutaneous lymph node syndrome, Kawasaki disease, adrenal cortex hormones, corticosteroid, methylprednisolone, dexamethasone.
Data collection process
The quality of the included studies was appraised by assessing allocation concealment, generation of the allocation sequence, and inclusion of all randomized participants. The risk of bias assessment was according to the Cochrane Handbook for Systematic Reviews of Interventions.
Data items
The primary outcome was the incidence of CAL. The secondary outcome was the duration of fever after intervention. Reported adverse events were also collected for meta-analysis.
Risk of bias across studies
The potential of publication bias was assessed using funnel plots and two statistical tests as Harbord's modified test and Peters' test. Statistical heterogeneity was assessed using the I 2 statistics. 15 We assigned adjectives of low, moderate, and high I 2 values of 25%, 50%, and 75%. The 95% confidence interval (CI) of I 2 was also calculated to avoid false negative result of heterogeneity.
Synthesis of results and summary measures
The risk of CAL was measured as odds ratio as it gave symmetric results for events and free risk. The duration of fever was measured in days. The adverse event was measured in risk difference. The effect sizes were pooled together using both the fixed effects model and random effects model as there were many small studies and high heterogeneity between studies. 16, 17 Meta-regression was also used, especially when the continuous variable such as duration and dose were involved. Furthermore, age, female percentage, fever duration, the duration of illness before corticosteroid therapy and the duration of illness before corresponding IVIG therapy were regressed against the odds ratio of CAL between the corticosteroids and control groups.
All analyses were conducted using Stata software (StataCorp. 2015. College Station, TX, USA).
Results

Study selection
A total of 240 citations were retrieved by the online search. Among them 22 entered the stage of full text review. Two studies were excluded because they focused on the steroid effect on chronic change of CAL and all the enrolled patients received steroid therapy. Another study was excluded because treatment process data were not available. Therefore, 19 studies fulfilled eligibility criteria and were included for analysis.
Study characteristics
The characteristics of the included studies are shown in Table 1 . The publication time ranged from 1999 to 2016. Many of them had a small sample size, and the median sample size was 94. Only one study had less male patients enrolled, which reflected the fact that Kawasaki disease is more prevalent in male. Fifteen studies only included Japanese patients. The average age was between 22.8 months and 64 months. The average age of Hashino et al., 2001 was older than usual, 23 which might be caused by the relative few subjects enrolled (29 patients) and outliers up to 10 years old. The treatment regimens are summarized in Table 2 . All the studies initially used intravenous route. Eleven studies used corticosteroid as primary therapy adjuvant to IVIG, among them three studies used risk score to select high risk patients as target. Eight studies used corticosteroid as rescue therapy and only one of them had the subgroup which used corticosteroid as adjuvant therapy in addition to IVIG. 16 Eleven studies recorded the duration of fever and 12 studies reported adverse events in both corticosteroid and control groups.
There was no significant asymmetry by visual inspection of the funnel plot. As there were more than 10 studies included in this meta-analysis, statistical test of publication bias was reasonable. The Harbord's modified test gave bias as 0.57 (95% CI: À2.08e3.22, p Z 0.655). The Peters' test gave bias as 0.23 (95% CI: À73.3e75.2, p Z 0.995). Both statistical tests suggest no publication bias.
Eighteen studies were included in quantitative synthesis because one study had no patients with CAL in both corticosteroid group and control group. There was statistically significant difference between study heterogeneity (heterogeneity chi-square 79.75, p Z 0.001). The I 2 was high.
(76%, 95% CI: 62e85%), so these studies were heterogeneous.
Synthesis of results
The pooled odds ratio by the fixed effects model for the effect of corticosteroid on incidence of CAL in patients with KD was 0.724 (95% CI: 0.571e0.917; p Z 0.007), indicating a significant reduction in incidence for patients treated with corticosteroid than those treated without corticosteroid. With a conservative estimated baseline incidence of CAL of 5% in patients of KD, there would be 13.3 (95% CI 4e20.8) CAL cases avoided per 1000 patients, giving a number needed to treat of 75.2. The forest plot is given in Fig. 1 . There were 7 studies reporting fever duration with standard error. As shown in Fig. 2 , the decrease of fever duration after steroid treatment was statistically significant: 0.85 day (95% CI 0.67e1.02) shorter in corticosteroids group in fixed effects model and 1.17 day (95% CI 0.66e1.67) shorter in random effects model.
We performed meta-analysis of risk difference for adverse events, because there were 5 studies with zero adverse event in one group. The risk difference is 0.01 (95% CI À0.01e0.04) in fixed effects model and 0.01 (95% CI À0.01e0.03) in random effects model. Both are not statistically significant.
Subgroup analysis Randomized controlled trials
To explore the potential source of heterogeneity and find out confounding factor, we performed analysis on predefined subgroups. For randomized controlled trials, the odds ratio was 0.32 (95% CI 0.20e0.52) in fixed effects model and 0.32 (95% CI 0.12e0.83) in random effects model.
Primary versus rescue therapy
Corticosteroid usage in Kawasaki disease differed in the purpose: primary therapy or rescue. The rescue therapy was given to no-responders to IVIG. The forest plot of each group is showed in Fig. 3 . The risk reduction of CAL was much larger in the primary therapy group (OR 0.39, 95% CI 0.27e0.56 in fixed effects model and OR 0.4, 95% CI 0.23e0.71 in random effects model). On the other hand, there was a trend of increase of CAL in the rescue group, though not statistically significant (OR 1.26, 95% CI 0.91e1.76 in fixed effects model and OR 1.69, 95% CI 0.66e0.43 in random effects model).
Japanese versus non-Japanese patients
We divided the studies to 2 subgroups by ethnicity because the well-known epidemiological difference between Japanese and non-Japanese patients. 40 The forest plot of each group was shown in Fig. 4 . The risk reduction was statistically significant in Japanese groups (OR 0.56, 95% CI 0.42e0.75 in fixed effects model and OR 0.63, 95% CI 0.31e1.31 in random effects model). In contrast, corticosteroid tended to increase CAL in non-Japanese groups, though not statistically significant (OR 1.45, 95% CI Primary therapy on patients with high risk score Primary therapy with corticosteroid was suggested on patients with high risk score by Japanese Society of Pediatrics. The result is showed in Fig. 5 . These studies were very homogeneous with I 2 as 0.2%. The odd ratio was 0.22 (95% CI 0.12e0.38) in fixed effects model and 0.23 (95% CI 0.13e0.41) in random effects model.
Meta-regression
The effect of duration illness before corticosteroid therapy (days) on odds ratio of CAL risk was statistically significant (slope 0.29, 95% CI 0.02e0.56.), so was duration illness before IVIG therapy (slope 0.24, 95% CI 0.02e0.47.)
Discussion
In this meta-analysis, corticosteroid showed an effect on reducing the risk of CAL in Kawasaki disease. The result is more obvious in studies of high quality and makes it more convincible. On the other hand, the odds ratio varied greatly across different treatment regimens and target: as primary therapy adjuvant to IVIG or rescue alternative to IVIG. In the rescue group, corticosteroid may increase the incidence of CAL, though not statistically significantly different. This result may give more evidence in the next modification of American Heart Association guideline, which now suggests that corticosteroid treatment is restricted to children in whom more than 2 doses of IVIG have been ineffective in alleviating fever and acute inflammation. They may be the vulnerable group for rescue corticosteroid therapy.
Further subgroup analysis revealed another important finding: different effect of corticosteroid on CAL in patients with different ethnicity. The risk reduction of CAL was statistically significant in Japanese groups but not significant in non-Japanese groups in fixed effect model. Random effect model did not give conclusive results in Japanese groups but the tendency of risk reduction was more obvious compared to over-all analysis. There were some susceptible genes related to T lymphocyte response found in Japanese. 40 Corticosteroid modulate T lymphocyte response and may reduce the CAL through it in Japanese patients. The effect was not found in non-Japanese patients as our study showed that corticosteroid tended to increase CAL in nonJapanese groups, though not statistically significant both in fixed effects model and in random effects mode. Therefore, corticosteroid might be used cautiously in nonJapanese patients.
Our meta-regression result debunks the methodological errors of previous meta-analysis. 18 The previous analysis emphasizing the importance of therapy timing through meta-regression of CAL odds ratio to duration of illness before the treatment of corticosteroid. We perform the another meta-regression of CAL odds ratio to duration illness before the corresponding treatment of IVIG. Since Figure 5 . The forest plot for the effect of corticosteroids on coronary arterial lesions in patients with high risk scores. The area of each square is proportional to the study's weight in the meta-analysis. The 95% CI is represented by horizontal lines. The overall meta-analyzed measure of effect is represented as a dashed vertical line and diamonds with the lateral points of which indicate confidence intervals. the timing of corticosteroid therapy was mostly determined by the purpose of corticosteroid therapy, when corticosteroid was used as rescue therapy the patients naturally had longer duration of illness and were certainly nonresponders to IVIG. When the corticosteroid was used as primary therapy, the treatment timing of IVIG was largely correlated with the timing of corticosteroid therapy, so the meta-regression result was similar if the independent variable was set as the duration of illness of corresponding IVIG treatment. We found the concurrent administration of IVIG and corticosteroid on selected high-risk patient is more important than the timing of corticosteroid alone.
Although our meta-analysis seems to suggest worse effect on CAL in corticosteroid rescue therapy, there is another interpretation for this result. Now the practice is usually use of corticosteroid therapy as alternative to other rescue therapy, mostly another dose of IVIG. However, in the primary therapy, corticosteroid is used as adjuvant to IVIG. This may be the key of the opposite effect of corticosteroid in the two groups. In the study done by Kobayashi et al., 19 the corticosteroid plus IVIG group had lower CAL rate not only compared to the IVIG alone rescue therapy but also to the corticosteroid alone group. In the earliest study of such investigation by Shinohara et al., 20 IVIG was not well established as primary therapy, so there were a group using corticosteroid alone as primary therapy and a group using corticosteroid and IVIG simultaneously as primary therapy. The latter had a significantly lower CAL rate compared to the corticosteroid alone group (1.6% vs 10%). These both suggest a synergistic effect of combined corticosteroid and IVIG simultaneously. As corticosteroid is a least expensive anti-inflammatory agent, further prospective study of combination of corticosteroid and IVIG is promising.
The secondary outcome is straightforward: corticosteroids may significantly decrease the duration of fever after treatment, whether used as primary or rescue therapy. Though it can make the patients less suffering, it may interfere the clinical judgment at the same time.
There are some limitations. The main problem of metaanalysis in Kawasaki disease treatment is that there is a discrepancy on the diagnosis criteria of Kawasaki disease itself and the diagnosis criteria of CAL by echocardiography between Japan and Western world. The Diagnostic criteria of CAL in Japan use absolute value instead of Z-core, and the difference cut point of Z-score across the studies may cause inconsistency between studies. Moreover, as we know the CAL regressed by time, the accessing timing of CAL will have effect on the result of incidence in CAL. In the included studies, some studies defined CAL incidence as all the detected CAL over a period. The previous meta-analysis does not choose a consistent accessing time for CAL to minimize the effect of CAL regression even when data is available. 18 We corrected this method flaw in our analysis but the different accessing time still caused high heterogeneity. The better end-point may be the incidence of giant aneurysm, as previous studies showed that it was associated with sudden death. It was a rare event and needed long term follow up, but most studies did not describe the data. Fifteen studies in this meta-analysis were performed in Japan, which inevitably made us cautious during extrapolating the results to other Ethnic groups.
Furthermore, the risk score may not be applied well outside Japan. 21 A local scoring system development is crucial for application of this meta-analysis result. As for the limitation of this study, the severe adverse event such as Kawasaki shock syndrome were not well-reported in these studies, 22 so we cannot rule the other potential side effect of corticosteroids.
Conclusion
We demonstrated an overall reduction in incidence of coronary artery lesions with the use of corticosteroid as initial and adjuvant treatment for Kawasaki disease. Corticosteroids, when used as an adjuvant to IVIG in Japanese patients, was not harmful and may decrease the rate of CAL, but did not have beneficial effect on the rate of CAL in non-Japanese patients, on whom corticosteroid should be cautiously used.
Conflicts of interest
All the authors have no conflicts of interest to disclose.
